Current Report Filing (8-k)
22 December 2020 - 8:32AM
Edgar (US Regulatory)
0000906709
false
--12-31
0000906709
2020-12-15
2020-12-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): December 15, 2020
NEKTAR
THERAPEUTICS
(Exact
Name of Registrant as Specified in Charter)
Delaware
|
|
0-24006
|
|
94-3134940
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
455
Mission Bay Boulevard South
San
Francisco, California 94158
(Address
of Principal Executive Offices and Zip Code)
Registrant’s
telephone number, including area code: (415) 482-5300
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
symbol(s)
|
|
Name
of each exchange on
which registered
|
Common Stock, $0.0001
par value
|
|
NKTR
|
|
NASDAQ Global Select
Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.03. Amendment to Article of Incorporation or Bylaws; Change in Fiscal Year.
On
December 15, 2020, the Board of Directors of Nektar Therapeutics (the “Company”) approved an amendment and restatement
of the Company’s amended and restated bylaws to designate the federal district courts of the United States of America as
the exclusive forum for any action asserting a claim arising under the Securities Act of 1933, as amended, unless the Company
consents in writing to the selection of an alternative forum.
The
foregoing description of the Company’s amended and restated bylaws is qualified in its entirety by reference to the amended
and restated bylaws of the Company, which are attached hereto as Exhibit 3.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
By:
|
/s/
Mark A. Wilson
|
|
|
Mark A. Wilson
|
|
|
General Counsel and Secretary
|
|
|
|
|
Date:
|
December 21, 2020
|
2
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From Apr 2024 to May 2024
Nektar Therapeutics (NASDAQ:NKTR)
Historical Stock Chart
From May 2023 to May 2024